619 related articles for article (PubMed ID: 21635987)
1. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.
Ovalle F
Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987
[TBL] [Abstract][Full Text] [Related]
2. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
Dailey G
Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
[TBL] [Abstract][Full Text] [Related]
3. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.
Pi-Sunyer FX
Postgrad Med; 2008 Jul; 120(2):5-17. PubMed ID: 18654064
[TBL] [Abstract][Full Text] [Related]
4. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus.
Blonde L
Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S4-11. PubMed ID: 19952303
[TBL] [Abstract][Full Text] [Related]
5. Beyond glycemic control: treating the entire type 2 diabetes disorder.
Brunton S
Postgrad Med; 2009 Sep; 121(5):68-81. PubMed ID: 19820276
[TBL] [Abstract][Full Text] [Related]
6. Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk.
Peters AL
Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S20-7. PubMed ID: 19952300
[TBL] [Abstract][Full Text] [Related]
7. Metabolic syndrome: treatment of hypertensive patients.
Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
[TBL] [Abstract][Full Text] [Related]
8. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
Krum H; McMurray JJ; Horton E; Gerlock T; Holzhauer B; Zuurman L; Haffner SM; Bethel MA; Holman RR; Califf RM
Cardiovasc Ther; 2010 Apr; 28(2):124-32. PubMed ID: 20184589
[TBL] [Abstract][Full Text] [Related]
9. Complementing insulin therapy to achieve glycemic control.
Barnett AH
Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
Tandon N; Ali MK; Narayan KM
Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
[TBL] [Abstract][Full Text] [Related]
11. Sodium-glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus.
Guthrie RM
Postgrad Med; 2013 May; 125(3):21-32. PubMed ID: 23748504
[TBL] [Abstract][Full Text] [Related]
12. Redefining treatment success in type 2 diabetes mellitus: Comprehensive targeting of core defects.
Cefalu WT; Richards RJ; Melendez-Ramirez LY
Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S39-47. PubMed ID: 19952302
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular manifestations of insulin resistance.
Chahwala V; Arora R
Am J Ther; 2009; 16(5):e14-28. PubMed ID: 19114874
[TBL] [Abstract][Full Text] [Related]
14. Long-term benefits of insulin therapy and glycemic control in overweight and obese adults with type 2 diabetes.
Caballero AE
J Diabetes Complications; 2009; 23(2):143-52. PubMed ID: 18413192
[TBL] [Abstract][Full Text] [Related]
15. Impact of weight gain on outcomes in type 2 diabetes.
Ross SA; Dzida G; Vora J; Khunti K; Kaiser M; Ligthelm RJ
Curr Med Res Opin; 2011 Jul; 27(7):1431-8. PubMed ID: 21599553
[TBL] [Abstract][Full Text] [Related]
16. Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay.
Niswender K
Diabetes Obes Metab; 2010 Apr; 12(4):267-87. PubMed ID: 20380648
[TBL] [Abstract][Full Text] [Related]
17. Metabolic risk during antipsychotic treatment.
Newcomer JW
Clin Ther; 2004 Dec; 26(12):1936-46. PubMed ID: 15823759
[TBL] [Abstract][Full Text] [Related]
18. Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk.
Mannucci E; Rotella CM
Nutr Metab Cardiovasc Dis; 2008 Nov; 18(9):639-45. PubMed ID: 18849155
[TBL] [Abstract][Full Text] [Related]
19. Diabetes mellitus: a cardiovascular disease.
Candido R; Srivastava P; Cooper ME; Burrell LM
Curr Opin Investig Drugs; 2003 Sep; 4(9):1088-94. PubMed ID: 14582453
[TBL] [Abstract][Full Text] [Related]
20. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
Defronzo RA; Mehta RJ; Schnure JJ
Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
